Peptide · Fact sheet
Linaclotide
Also known as Linzess · guanylate cyclase-C agonist
Linaclotide is FDA approved as Linzess for specific forms of constipation and constipation-predominant irritable bowel syndrome in defined adult and pediatric age groups. It is not a systemic recovery, metabolic, or gut-healing peptide.
What is Linaclotide?
Linaclotide is a 14-amino-acid peptide that activates guanylate cyclase-C on the intestinal surface and is minimally absorbed into the bloodstream.
Its local action increases intestinal fluid and can change pain signaling, which is why evidence is tied to constipation outcomes.
Benefits & claims
It demonstrates that an oral peptide can work primarily at the gut surface without needing broad systemic exposure.
The same secretory mechanism that helps constipation also explains the main risk: diarrhea and dehydration.
What the evidence supports
- Phase 3 trials found improvements in bowel-frequency and abdominal-symptom endpoints compared with placebo.
- Pediatric trials supported selected age-specific label expansions rather than unrestricted use in children.
Research areas
- IBS with constipation
- Chronic idiopathic constipation
- Pediatric functional constipation
- Abdominal pain and bowel symptoms
- Other carefully defined disorders of gut sensation and motility
Dosage & frequency
Product-specific label informationLinzess has different labeled amounts by constipation diagnosis and age. The adult IBS-C amount should not be applied to every constipation population.
Linzess: adult IBS-C
Adults with irritable bowel syndrome with constipation
- Amount
- 290 mcg
- Frequency
- Once daily
- Route studied or labeled
- Oral
Diagnosis-specific label.
Linzess: adult CIC
Adults with chronic idiopathic constipation
- Amount
- 145 mcg; 72 mcg may be used based on presentation or tolerability
- Frequency
- Once daily
- Route studied or labeled
- Oral
Diagnosis-specific label.
Linzess: pediatric IBS-C
Patients age seven years and older with IBS-C
- Amount
- 145 mcg
- Frequency
- Once daily
- Route studied or labeled
- Oral
Contraindicated below age two; pediatric diagnosis matters.
Linzess: pediatric functional constipation
Patients age two years and older with functional constipation
- Amount
- 72 mcg
- Frequency
- Once daily
- Route studied or labeled
- Oral
Different pediatric constipation indication.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- The approved oral capsule acts mainly within the gut.
Interactions & precautions
- The label states that drug-drug interaction studies have not been conducted; systemic exposure is negligible after labeled oral use.
What is still unresolved
- Individual response and tolerability vary; the label contains diagnosis- and age-specific restrictions.
Side effects & risks
- The label carries a boxed warning about serious dehydration risk in children younger than 2 years.
- Severe diarrhea can occur and is the main clinically important adverse effect.
- It is contraindicated when mechanical gastrointestinal obstruction is known or suspected.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesMultiple controlled trials and indication expansions support the labeled gastrointestinal uses. The peptide's local action and evidence do not establish general microbiome, anti-inflammatory, or wellness benefits.
Studies
Controlled trial of abdominal pain and bowel outcomes with randomized withdrawal.
Age-specific Phase 3 evidence supporting a pediatric indication.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Digestion: reported experiences
Persistent diarrhea disrupted daily life
An author described about a month of bowel movements shifting from absent to substantial diarrhea. Their reply described it as annoying rather than painful.
Reported use in this account
- Product
- Linzess
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About one month
This is one person's experience with Linzess; diagnosis, other treatments and severity were not independently checked.
Read the original accountInitial relief became less reliable
A person with longstanding constipation described no initial effect, then about two months of relief from bloating with loose stools, followed by much less reliable bowel movements.
Reported use in this account
- Product
- Linzess; the source's amount has an unresolved unit
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- About four months
The source's amount has an unresolved unit and is not reproduced. The fluctuating response does not establish tolerance; no clinical record or controlled comparison was supplied.
Read the original accountSatisfied without diarrhea
A different commenter said they were pleased with Linzess and did not experience diarrhea.
Amount, frequency, route and duration could not be confirmed for this account.
This brief comment gives no duration, diagnosis or measured outcome; it does not establish typical tolerability.
Read the original accountNo benefit reported
Another commenter in a constipation discussion said Linzess had done nothing for them.
Amount, frequency, route and duration could not be confirmed for this account.
The comment lacks duration, diagnosis and concurrent-treatment details.
Read the original accountNo clear change: reported experiences
No benefit reported
Another commenter in a constipation discussion said Linzess had done nothing for them.
Amount, frequency, route and duration could not be confirmed for this account.
The comment lacks duration, diagnosis and concurrent-treatment details.
Read the original accountApproval status
Current FDA labeling covers IBS with constipation, chronic idiopathic constipation, and pediatric functional constipation in the specific age groups listed for each indication.
Approved uses
- The adult and age-specific pediatric constipation indications in current Linzess labeling
FDA approved for labeled constipation disorders
Linaclotide is approved under the Linzess label for specific adult and pediatric constipation-related indications. The approval is label-specific.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Which patients will have a durable response rather than intolerable diarrhea
- Long-term comparative effectiveness across approved constipation medicines
- Whether other formulations can separate pain relief from secretory effects
- Benefits outside labeled constipation disorders
Summary
Linzess is approved for specific constipation disorders, not general gut repair or optimization.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Linzess
Current age-specific indications, boxed warning, contraindications, and safety information.
- pubmedRandomized Phase 3 IBS-C trial
Controlled trial of abdominal pain and bowel outcomes with randomized withdrawal.
- pubmedRandomized pediatric functional-constipation trial
Age-specific Phase 3 evidence supporting a pediatric indication.